CareFirst Holdings enters into a Strategic Partnership with Exosome Diagnostics
Washington, DC, August 24, 2017 – CareFirst BlueCross BlueShield, through an affiliate, recently entered into a strategic partnership with Exosome Diagnostics, Inc. England Securities served as financial advisor to CareFirst BlueCross BlueShield in connection with the structuring of this partnership.
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, and point of care instrument for protein capture and analysis, Shahky™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are diagnosed, treated and monitored.
CareFirst BlueCross BlueShield, based in Baltimore, MD, is an independent licensee of the Blue Cross and Blue Shield Association. Through its affiliates and subsidiaries, CareFirst BlueCross BlueShield offers a comprehensive portfolio of health insurance products and administrative services to 3.4 million individuals and groups in Maryland, the District of Columbia and Northern Virginia.
About England & Company
With offices in Houston, New York, and Washington, DC, England & Company is an independent investment banking and advisory boutique dedicated to serving middle-market companies. Since its founding in 2003, the firm has provided comprehensive advice on mergers and acquisitions, private capital raising, financial restructuring, fairness opinions, and other strategic initiatives to the executive teams, boards of directors, and financial sponsors of public and private companies.
Investment banking services are provided by England Securities LLC, a registered broker-dealer and member of FINRA and SIPC.